Skip to main content
. Author manuscript; available in PMC: 2018 Mar 13.
Published in final edited form as: J Allergy Clin Immunol. 2017 Aug 8;141(2):522–524. doi: 10.1016/j.jaci.2017.07.016

FIG. 1.

FIG. 1

JAK2 and JAK3 inhibitors in clinical trials for immunologic disorders. JAK2 and JAK3, nonreceptor tyrosine kinases associated with different cytokine receptors, have been targets in patients with diseases, such as rheumatoid arthritis, graft-versus-host disease, atopic dermatitis, and systemic lupus erythematosus.